Table 5 |
||||
|
Key features of the protocols for comparison |
||||
| Feature |
PathVysion |
PharmDx |
INFORM |
CISH |
|
|
||||
| Reagents |
Preparation required |
Ready to use |
Ready to use |
Ready to use |
| Stability of reagents |
pH requires checking |
OK |
OK |
OK |
| DAPI |
Bright |
Low intensity |
Not provided |
- |
| Background |
Orange fluorescence |
Strong; green fluorescence |
Faint; green fluorescence |
- |
| Stability of signal |
Good |
Rapid quenching of FITC signal |
Good |
Excellent |
| HER2 probe |
Spectrum Orange; clear signal but high background fluorescence |
Texas red; strong clear signal |
FITC; strong clear signal |
Chromogenic; peroxidase-based immunodetection, clear signal |
| CEP17 probe |
FITC; very strong signal, with blurring of large signals |
FITC; faint and transient |
- |
- |
| Tissue morphology |
Poor definition; control with H&E to view areas of interest |
Very poor definition; control with H&E to view areas of interest |
Poor definition; control with H&E to view areas of interest |
Good definition, allowing simultaneous analysis of amplification and histopathology |
| Microscope |
Fluorescent |
Fluorescent |
Fluorescent |
Normal light |
| Storage |
1 year at -20°C |
1 year at -20°C |
1 year at -20°C |
Long period at ambient temperature |
| Threshold |
OK |
OK |
CISH threshold must be applied and borderline cases must be evaluated with a dual-probe
method (5–10) |
|
|
|
||||
|
DAPI, 4,6-diamidino-2-phenylindole; HER2, human epidermal growth factor receptor 2; CEP17, chromosome enumeration probe 17; FITC, fluorescein isothiocyanate; H&E, haematoxylin and eosin staining; CISH, chromogenic in situ hybridisation. |
||||
|
Cayre et al. Breast Cancer Research 2007 9:R64 doi:10.1186/bcr1770 |
||||
